Market Analysis and Insights: Global Gonorrhea Therapeutics Market
Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospects.
The global Gonorrhea Therapeutics market size is projected to reach US$ 1427.7 million by 2028, from US$ 1052.4 million in 2021, at a CAGR of 4.0% during 2022-2028.
The latest trend gaining momentum in the market is Advent of vaccine for prevention of gonorrhea. Gonorrhea is a major public health concern globally. It is considerably affecting the reproductive health of people and increasing the spread of human immunodeficiency virus (HIV). The currently available treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae due to the rapid emergence of the antibiotic-resistant strains of this bacterium. Therefore, the prevention of the disease seems to be a more appropriate approach for controlling the spread of Neisseria gonorrhoeae.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gonorrhea Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gonorrhea Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gonorrhea Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gonorrhea Therapeutics market.
Global Gonorrhea Therapeutics Scope and Market Size
Gonorrhea Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Gonorrhea Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Monotherapy
Dual Therapy
Segment by Application
Clinics
Hospitals
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bharat Pharmaceuticals
GlaxoSmithKline
Merck
Pfizer
Alopexx Pharmaceuticals
AstraZeneca
Debiopharm Group
Melinta Therapeutics
Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospects.
The global Gonorrhea Therapeutics market size is projected to reach US$ 1427.7 million by 2028, from US$ 1052.4 million in 2021, at a CAGR of 4.0% during 2022-2028.
The latest trend gaining momentum in the market is Advent of vaccine for prevention of gonorrhea. Gonorrhea is a major public health concern globally. It is considerably affecting the reproductive health of people and increasing the spread of human immunodeficiency virus (HIV). The currently available treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae due to the rapid emergence of the antibiotic-resistant strains of this bacterium. Therefore, the prevention of the disease seems to be a more appropriate approach for controlling the spread of Neisseria gonorrhoeae.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gonorrhea Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gonorrhea Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gonorrhea Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gonorrhea Therapeutics market.
Global Gonorrhea Therapeutics Scope and Market Size
Gonorrhea Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Gonorrhea Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Monotherapy
Dual Therapy
Segment by Application
Clinics
Hospitals
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bharat Pharmaceuticals
GlaxoSmithKline
Merck
Pfizer
Alopexx Pharmaceuticals
AstraZeneca
Debiopharm Group
Melinta Therapeutics
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.